However, recent studies point out that acquisition of additional mutations (Asxl1, Ezh2, or Dnmt3a) can also alter transcriptional program and can accelerate disease transformation from early stage MPN (PV/ET) toward MF in a scenario where low allele expression of the mutant driver might not be sufficient. Here, EZH2 is linked to myeloproliferative disorder.